CD8A and neoplasm: As illustrated, patients belonging to the Luminal-CD8+Thigh subgroup exhibited significantly elevated tumor neoantigen burden across both the TCGA and IMvigor210 cohorts (Fig. 4a and Supplementary Fig. 3B).